Independent
Tenure on this board
7.1 yrs
Also a director at
Sarepta Therapeutics Inc (SRPT)
Meeting calendar
RLAY · Annual meeting · Tuesday, June 9, 2026
Relay Therapeutics Inc
2 nominees · 4 ballot items.
Election of two Class III directors; non-binding advisory vote on executive compensation; ratification of Ernst & Young LLP as independent registered public accounting firm for FY2026; approval to amend certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000.
Market cap
$3.8B
1Y TSR
+408.3%
Board grade
C
Record date
Apr 13, 2026
Filing
DEF 14A
Meeting concluded · Jun 9, 2026
Follow how the vote landed and what changed on Relay Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Election of Class III Directors
ManagementBoard: FORElect two Class III directors (Douglas S. Ingram and Claire Mazumdar, Ph.D.) to serve three-year terms expiring in 2029.
- 2
Non-Binding Advisory Vote on Compensation of our Named Executive Officers
ManagementBoard: FORAdvisory (non-binding) vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.
More detail
Proposal 2 is a management-sponsored, non-binding advisory "say-on-pay" vote seeking shareholder approval of executive compensation as disclosed in the proxy materials. While advisory and not binding, the board and compensation committee will consider the outcome when setting future pay policies. The proposal asks shareholders to approve the overall compensation framework, including base salaries, annual incentive bonuses tied to corporate and individual performance, and long-term equity incentives (primarily time-based options in 2025). Management emphasizes alignment with stockholder interests via at-risk pay and equity incentives and cites its peer benchmarking and use of an independent compensation consultant. The company notes recent engagement with stockholders following prior say-on-pay results and explains its rationale for time-based options (rather than performance-based awards) given the pre-commercial stage and the challenges linking clinical milestones or financial metrics to shareholder value. A vote FOR indicates support for the board’s compensation approach, while a vote AGAINST or ABSTAIN would be advisory feedback the board expects to consider in future compensation decisions.
- 3
Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for Fiscal Year 2026
ManagementBoard: FORRatify the audit committee’s selection of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 4
Amendment to Certificate of Incorporation to Increase Authorized Shares of Common Stock
ManagementBoard: FORApprove an amendment to the company’s certificate of incorporation to increase authorized shares of common stock from 300,000,000 to 450,000,000.
More detail
Proposal 4 requests shareholder approval to amend the Fourth Amended and Restated Certificate of Incorporation to increase authorized common shares from 300 million to 450 million. Management argues the additional shares will provide flexibility to raise capital, support equity compensation plans, enable strategic transactions, and respond to market opportunities without needing further shareholder approval except where legally required. The company notes it currently has limited available shares for future issuance after reserving shares for outstanding awards and its ATM sales agreement; approval would increase the available pool. The board acknowledges potential dilution and anti‑takeover implications but states no specific issuance is planned and reserves the right to abandon the amendment if not in stockholders’ best interests. The proposal would become effective upon filing the Certificate of Second Amendment with the Delaware Secretary of State.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
1.1 yrs
Also a director at
Bicara Therapeutics Inc (BCAX)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 14.6% | 27,904,963 | $278M |
| 2 | Commodore Capital LP | 8.9% | 17,000,000 | $169M |
| 3 | Casdin Capital, LLC | 7.5% | 14,418,574 | $143M |
| 4 | PERCEPTIVE ADVISORS LLC | 5.1% | 9,751,141 | $97M |
| 5 | Bellevue Group AG | 4.1% | 7,793,318 | $78M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 7,387,465 | $74M |
| 7 | STATE STREET CORP | 3.3% | 6,233,545 | $62M |
| 8 | BlackRock, Inc. | 3.1% | 5,996,372 | $60M |
| 9 | Nextech Invest, Ltd. | 2.9% | 5,526,506 | $55M |
| 10 | BlackRock, Inc. | 2.3% | 4,488,342 | $45M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Relay Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Relay Therapeutics Inc 2026 annual meeting?
- Relay Therapeutics Inc (RLAY) holds its 2026 annual shareholder meeting on Tuesday, June 9, 2026.
- What is the record date for the Relay Therapeutics Inc 2026 meeting?
- The record date for the Relay Therapeutics Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Relay Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Relay Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Relay Therapeutics Inc 2026 meeting?
- Shareholders will vote on 4 proposals at the Relay Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.